Welcome to our dedicated page for Galectin Therapeutics news (Ticker: GALT), a resource for investors and traders seeking the latest updates and insights on Galectin Therapeutics stock.
Galectin Therapeutics Inc. develops therapeutics that target galectin proteins, with its lead program focused on belapectin, a carbohydrate-based galectin-3 inhibitor for MASH cirrhosis and portal hypertension. Company updates commonly cover NAVIGATE clinical-trial results, biomarker analyses, medical-conference presentations, journal publications, and FDA communications related to the belapectin development program.
News also includes financial results, research and development spending, cash-resource updates, credit financing, board composition, and investor or key-opinion-leader events. Galectin has also described additional development interests in combination immunotherapy for advanced head and neck cancers and other malignancies.
Galectin Therapeutics (NASDAQ: GALT) reported its Q1 2024 financial results and provided a business update. The NAVIGATE Phase 2b/3 trial of belapectin in liver cirrhosis due to MASH continues as planned, with an interim top-line readout expected late Q4 2024 after a positive fifth DSMB meeting.
Q1 financials show $23.6M in cash with an additional $10M available from a new line of credit. R&D expenses decreased to $8.1M from $8.8M YoY, while G&A expenses increased slightly to $1.6M from $1.5M. The net loss remained constant at $11.5M or ($0.19) per share YoY.
Corporate updates include the appointment of Dr. Khurram Jamil as VP of Clinical Development. The company mourns the loss of Dr. Stephen A. Harrison, a key figure in the belapectin program.
Galectin Therapeutics Inc. (NASDAQ: GALT) will participate in the H.C. Wainwright BioConnect Conference, presenting at the fireside chat on May 20, 2024, at 4:00 PM ET at the Nasdaq World Headquarters in New York City. The management team will be available for one-on-one meetings, and a webcast link will be provided on the Company's website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.